Bart Barlogie Selected Research

Chromosome Aberrations (Chromosome Abnormalities)

6/2013	Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
11/2012	Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.
3/2011	International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.
1/2011	Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.
6/2010	Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms.
4/2009	Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma.
10/2008	Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.
5/2008	CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.
5/2008	Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1.
7/2007	Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bart Barlogie Research Topics

Disease

147	Multiple Myeloma 03/2022 - 02/2002
54	Neoplasms (Cancer) 01/2021 - 01/2002
19	Chromosome Aberrations (Chromosome Abnormalities) 06/2013 - 08/2002
10	Bone Diseases (Bone Disease) 09/2014 - 01/2002
8	Paraproteinemias (Monoclonal Gammopathy) 11/2020 - 02/2006
7	Disease Progression 01/2015 - 01/2002
6	Amyloidosis 06/2014 - 03/2002
5	Waldenstrom Macroglobulinemia (Macroglobulinemia) 01/2018 - 04/2003
5	Anemia 01/2018 - 04/2003
5	Monoclonal Gammopathy of Undetermined Significance 01/2018 - 01/2002
5	Aspergillosis 10/2011 - 07/2007
4	Hematologic Neoplasms (Hematological Malignancy) 12/2019 - 07/2007
4	Smoldering Multiple Myeloma 01/2018 - 10/2008
4	Thrombocytopenia (Thrombopenia) 07/2013 - 12/2005
4	Renal Insufficiency (Renal Failure) 11/2010 - 01/2003
4	Venous Thrombosis (Deep-Vein Thrombosis) 03/2006 - 08/2002
3	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 12/2019 - 01/2008
3	Leukemia 03/2015 - 08/2012
3	Bone Resorption 06/2013 - 02/2002
3	Fatigue 05/2011 - 04/2003
3	Testicular Neoplasms (Testicular Cancer) 05/2011 - 08/2002
3	Mucositis 02/2011 - 01/2003
3	Neoplasm Metastasis (Metastasis) 01/2008 - 12/2003
3	Thrombosis (Thrombus) 10/2007 - 06/2003
3	Peripheral Nervous System Diseases (PNS Diseases) 07/2006 - 04/2003
3	Infections 08/2004 - 03/2003
2	Carcinogenesis 01/2020 - 04/2006
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2019 - 06/2002
2	Plasmacytoma 01/2017 - 02/2007
2	Plasma Cell Leukemia 12/2015 - 06/2014
2	Castleman Disease (Castleman's Disease) 01/2013 - 07/2010
2	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 09/2012 - 12/2002
2	Venous Thromboembolism 01/2012 - 08/2006
2	Neutropenia 12/2010 - 08/2004
2	Activated Protein C Resistance (APC Resistance) 08/2006 - 06/2003
2	Immunoglobulin Light-chain Amyloidosis 12/2004 - 03/2002

Drug/Important Bio-Agent (IBA)

26	Thalidomide (Thalomid)FDA Link 06/2013 - 04/2002
22	Bortezomib (Velcade)FDA Link 11/2020 - 06/2003
15	Dexamethasone (Maxidex)FDA LinkGeneric 11/2020 - 03/2003
13	Melphalan (Alkeran)FDA LinkGeneric 06/2017 - 03/2002
11	Lenalidomide (CC 5013)FDA Link 11/2020 - 10/2003
11	Proteins (Proteins, Gene)FDA Link 12/2016 - 05/2002
9	Proteasome InhibitorsIBA 09/2017 - 03/2005
8	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2018 - 03/2004
8	AntigensIBA 01/2018 - 05/2002
7	Pharmaceutical PreparationsIBA 06/2014 - 01/2002
5	Messenger RNA (mRNA)IBA 04/2010 - 02/2003
4	Biological ProductsIBA 01/2021 - 07/2006
4	CytokinesIBA 01/2019 - 06/2003
4	Proteasome Endopeptidase Complex (Proteasome)IBA 12/2016 - 04/2009
4	galactomannanIBA 10/2011 - 07/2007
4	Immunoglobulins (Immunoglobulin)IBA 07/2008 - 06/2003
3	AlbuminsIBA 01/2018 - 02/2011
3	CreatinineIBA 01/2018 - 03/2002
3	Immunomodulating AgentsIBA 09/2017 - 12/2002
3	DNA (Deoxyribonucleic Acid)IBA 04/2017 - 01/2004
3	Monoclonal AntibodiesIBA 01/2016 - 10/2006
3	Antineoplastic Agents (Antineoplastics)IBA 02/2011 - 08/2005
3	Cyclin D1IBA 02/2010 - 01/2003
3	Prednisone (Sone)FDA LinkGeneric 07/2009 - 05/2002
2	Immunoglobulin G (IgG)IBA 11/2020 - 10/2016
2	Immunoglobulin M (IgM)IBA 01/2018 - 08/2014
2	Biomarkers (Surrogate Marker)IBA 01/2018 - 02/2007
2	Cyclin DIBA 04/2017 - 07/2005
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2017 - 08/2004
2	Histones (Histone)IBA 12/2016 - 05/2011
2	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 07/2014 - 07/2008
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 03/2014 - 06/2003
2	NF-kappa B (NF-kB)IBA 07/2013 - 08/2007
2	Indicators and Reagents (Reagents)IBA 01/2012 - 04/2004
2	Membrane Glycoproteins (Membrane Glycoprotein)IBA 01/2012 - 05/2008
2	Sodium Glutamate (Accent)IBA 10/2011 - 12/2010
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 12/2010 - 07/2006
2	VaccinesIBA 09/2010 - 11/2005
2	beta CateninIBA 03/2010 - 04/2009
2	Cyclin D3IBA 02/2010 - 01/2003
2	C-Reactive ProteinIBA 09/2009 - 10/2006
2	elotuzumabIBA 09/2009 - 05/2008
2	LigandsIBA 12/2008 - 02/2002
2	fludarabineIBA 12/2008 - 04/2003
2	Polysaccharides (Glycans)IBA 05/2008 - 07/2007
2	Heparitin Sulfate (Heparan Sulfate)IBA 09/2007 - 12/2003
2	Syndecan-1 (Syndecan 1)IBA 09/2007 - 12/2003
2	heparanaseIBA 09/2007 - 12/2003
2	EnzymesIBA 09/2007 - 12/2003
2	OligonucleotidesIBA 04/2007 - 12/2003
2	factor V LeidenIBA 08/2006 - 06/2003
2	Protein CIBA 08/2006 - 06/2003
2	Protein Isoforms (Isoforms)IBA 08/2004 - 07/2003

Therapy/Procedure

93	Therapeutics 01/2022 - 01/2002
23	Drug Therapy (Chemotherapy) 03/2022 - 08/2002
10	Stem Cell Transplantation 03/2022 - 01/2002
7	Transplantation 12/2015 - 01/2002
7	Autologous Transplantation 08/2014 - 05/2003
6	Immunotherapy 09/2012 - 05/2002
3	Cell Transplantation 12/2015 - 03/2006
2	Salvage Therapy 07/2013 - 10/2008
2	Induction Chemotherapy 02/2011 - 05/2002
2	Hematopoietic Stem Cell Transplantation 02/2010 - 03/2006
2	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 05/2008 - 03/2004